Skip to main content

Advertisement

Log in

Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia

  • Review Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Hepatitis B virus (HBV) is characterized by a high genetic heterogeneity since it replicates via a reverse transcriptase that lacks proofreading ability. Up to now, ten genotypes (A–J) have been described, with genotype A and D being ubiquitous but most prevalent in Europe and Africa, genotype B and C being confined to Asia and Oceania. Infections with other genotypes such as E, F, G and H are also occasionally observed in Asia. Genotype I is rare and can be found in Laos, Vietnam, India and China, whereas genotype J has been described in Japan and Ryukyu. Novel variants generated by recombination and co-infection with other genotypes have gradually gotten worldwide attention and may be correlated with certain clinical features. There are substantial differences in HBV infection regarding prevalence, clinical manifestation, disease progression and response to antiviral therapy. Due to the complex interplay among viral, host and environmental factors, the relationship between HBV genotypes and clinical profiles remains incompletely revealed. In general, genotype A is associated with better response to interferon therapy; genotype C, and to lesser extent B, usually represent a risk factor for perinatal infection and are associated with advanced liver diseases such as cirrhosis and hepatocellular carcinoma; genotype D may be linked with poor response to interferon therapy. Future studies with better design and larger sample size are warranted to further clarify the controversial issues and guide the day-to-day clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546–1555

  2. Norder H, Courouce AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004;47:289–309

  3. Shi YH. Correlation between hepatitis B virus genotypes and clinical outcomes. Jpn J Infect Dis 2012;65:476–482

  4. Zehender G, Ebranati E, Gabanelli E, et al. Enigmatic origin of hepatitis B virus: an ancient travelling companion or a recent encounter? World J Gastroenterol 2014;20:7622–7634

  5. Li GJ, Hue S, Harrison TJ, et al. Hepatitis B virus candidate subgenotype I1 varies in distribution throughout Guangxi, China and may have originated in Long An county, Guangxi. J Med Virol 2013;85:799–807

  6. Phung TB, Alestig E, Nguyen TL, et al. Genotype X/C recombinant (putative genotype I) of hepatitis B virus is rare in Hanoi, Vietnam—genotypes B4 and C1 predominate. J Med Virol 2010;82:1327–1333

  7. Haldipur BP, Walimbe AM, Arankalle VA. Circulation of genotype-I hepatitis B virus in the primitive tribes of Arunachal Pradesh in early sixties and molecular evolution of genotype-I. Infect Genet Evol 2014;27:366–374

  8. Araujo NM. Hepatitis B virus intergenotypic recombinants worldwide: an overview. Infect Genet Evol 2015;36:500–510

  9. Shen L, Yin W, Zheng H, et al. Molecular epidemiological study of hepatitis B virus genotypes in Southwest, China. J Med Virol 2014;86:1307–1313

  10. Perez-Losada M, Arenas M, Galan JC, et al. Recombination in viruses: mechanisms, methods of study, and evolutionary consequences. Infect Genet Evol 2015;30:296–307

  11. Yin J, Zhang H, Li C, et al. Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area. Carcinogenesis 2008;29:1685–1691

  12. Datta S, Roychoudhury S, Ghosh A, et al. Distinct distribution pattern of hepatitis B virus genotype C and D in liver tissue and serum of dual genotype infected liver cirrhosis and hepatocellular carcinoma patients. PLoS One 2014;9:e102573

  13. Wang Y, Shan X, Liang Z, et al. Deep sequencing analysis of HBV genotype shift and correlation with antiviral efficiency during adefovir dipivoxil therapy. PLoS One 2015;10:e131337

  14. Chauhan R, Singh AK, Rooge S, et al. Analysis of hepatitis B virus genotype changes in patients with chronic hepatitis B infection on tenofovir therapy. J Med Virol 2016;88:1364–1375

    Article  CAS  PubMed  Google Scholar 

  15. Li HM, Wang JQ, Wang R, et al. Hepatitis B virus genotypes and genome characteristics in China. World J Gastroenterol 2015;21:6684–6697

  16. Wei DH, Liu HZ, Huang AM, et al. A new trend of genotype distribution of hepatitis B virus infection in southeast China (Fujian), 2006–2013. Epidemiol Infect 2015;143:2822–2826

  17. Yano Y, Utsumi T, Lusida MI, et al. Hepatitis B virus infection in Indonesia. World J Gastroenterol 2015;21:10714–10720

  18. Attaullah S, Rehman S, Khan S, et al. Prevalence of hepatitis B virus genotypes in HBsAg positive individuals of Afghanistan. Virol J 2011;8:281

  19. Garmiri P, Rezvan H, Abolghasemi H, et al. Full genome characterization of hepatitis B virus strains from blood donors in Iran. J Med Virol 2011;83:948–952

  20. Saikia A, Bose M, Barman NN, et al. Molecular epidemiology of HBV infection in chronic hepatitis B virus infected patients in northeast India. J Med Virol 2015;87:1539–1548

  21. Elkady A, Tanaka Y, Kurbanov F, et al. Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. J Gastroenterol Hepatol 2008;23:474–481

  22. Lyoo KS, Hong SW, Song MJ, et al. Subgenotype and genetic variability in the precore/core regions of hepatitis B virus in Korean patients with chronic liver disease. Intervirology 2011;54:333–338

  23. Matsuura K, Tanaka Y, Hige S, et al. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 2009;47:1476–1483

  24. Sakamoto T, Tanaka Y, Orito E, et al. Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines. J Gen Virol 2006;87:1873–1882

  25. Khan A, Al BM, Tanaka Y, et al. Novel point mutations and mutational complexes in the enhancer II, core promoter and precore regions of hepatitis B virus genotype D1 associated with hepatocellular carcinoma in Saudi Arabia. Int J Cancer 2013;133:2864–2871

  26. Louisirirotchanakul S, Olinger CM, Arunkaewchaemsri P, et al. The distribution of hepatitis B virus genotypes in Thailand. J Med Virol 2012;84:1541–1547

  27. Andernach IE, Jutavijittum P, Samountry B, et al. A high variability of mixed infections and recent recombinations of hepatitis B virus in Laos. PLoS One 2012;7:e30245

  28. Mumtaz K, Hamid S, Ahmed S, et al. A study of genotypes, mutants and nucleotide sequence of hepatitis B virus in Pakistan: HBV genotypes in Pakistan. Hepat Mon 2011;11:14–18

  29. Sayan M, Dogan C. Genotype/subgenotype distribution of hepatitis B virus among hemodialysis patients with chronical hepatitis B. Ann Hepatol 2012;11:849–854

  30. Al BS, Sy BT, Ratsch BA, et al. Molecular epidemiology and genotyping of hepatitis B virus of HBsAg-positive patients in Oman. PLoS One 2014;9:e97759

  31. Zhang HW, Yin JH, Li YT, et al. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut 2008;57:1713–1720

  32. Tamada Y, Yatsuhashi H, Masaki N, et al. Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B. Gut 2012;61:765–773

  33. Ito K, Yotsuyanagi H, Yatsuhashi H, et al. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology 2014;59:89–97

  34. Wada N, Yasunaka T, Ikeda F, et al. Prevalence and outcomes of acute hepatitis B in Okayama, Japan, 2006-2010. Acta Med Okayama 2014;68:243–247

  35. Ding Y, Sheng Q, Ma L, et al. Chronic HBV infection among pregnant women and their infants in Shenyang, China. Virol J 2013;10:17

  36. Wen WH, Chen HL, Ni YH, et al. Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology 2011;53:429–436

  37. Li Z, Xie Z, Ni H, et al. Mother-to-child transmission of hepatitis B virus: evolution of hepatocellular carcinoma-related viral mutations in the post-immunization era. J Clin Virol 2014;61:47–54

  38. Yao QQ, Dong XL, Wang XC, et al. Hepatitis B virus surface antigen (HBsAg)-positive and HBsAg-negative hepatitis B virus infection among mother-teenager pairs 13 years after neonatal hepatitis B virus vaccination. Clin Vaccine Immunol 2013;20:269–275

  39. Ni YH, Chang MH, Wu JF, et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012;57:730–735

  40. Lee M, Yang H, Liu J, et al. Prediction models of long-term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013;58:546–554

  41. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134–1143

  42. Wen J, Song C, Jiang D, et al. Hepatitis B virus genotype, mutations, human leukocyte antigen polymorphisms and their interactions in hepatocellular carcinoma: a multi-centre case-control study. Sci Rep 2015;5:16489

  43. Kim DW, Lee SA, Hwang ES, et al. Naturally occurring precore/core region mutations of hepatitis B virus genotype C related to hepatocellular carcinoma. PLoS One 2012;7:e47372

  44. Tatsukawa M, Takaki A, Shiraha H, et al. Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients. BMC Cancer 2011;11:458

  45. Lee SA, Kim K, Kim H, et al. Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases. J Hepatol 2012;56:63–69

  46. Yan H, Yang Y, Zhang L, et al. Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma. Hepatology 2015;61:1821–1831

  47. Yin J, Zhang H, He Y, et al. Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. Cancer Epidemiol Biomarkers Prev 2010;19:777–786

  48. Liang TJ, Mok KT, Liu SI, et al. Hepatitis B genotype C correlated with poor surgical outcomes for hepatocellular carcinoma. J Am Coll Surg 2010;211:580–586

  49. Kim GA, Lee HC, Kim MJ, et al. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. J Hepatol 2015;62:1092–1099

  50. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002–2009

  51. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008;13:211–220

  52. Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008;2:102–110

  53. Liaw YF, Jia JD, Chan HLY, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011;54:1591–1599

  54. Raimondi S, Maisonneuve P, Bruno S, et al. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol 2010;52:441–449

  55. Chen X, Chen X, Chen W, et al. Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B. J Med Virol 2014;86:1705–1713

  56. Brunetto MR, Marcellin P, Cherubini B, et al. Response to peginterferon alfa-2a (40 KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 2013;59:1153–1159

  57. Seto WK, Liu K, Wong DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after 3 years of tenofovir treatment. J Hepatol 2013;59:709–716

  58. Su TH, Liu CJ, Tseng TC, et al. Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection. PLoS One 2013;8:e55916

  59. Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013;58:923–931

  60. Marcellin P, Buti M, Krastev Z, et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol 2014;61:1228–1237

  61. Chan HL, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 2014;146:1240–1248

  62. Hosaka T, Suzuki F, Kobayashi M, et al. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a 9-year longitudinal study. J Gastroenterol 2013;48:930–941

  63. Inoue J, Ueno Y, Wakui Y, et al. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepat 2011;18:206–215

  64. Zoulim F, Carosi G, Greenbloom S, et al. Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol 2015;62:56–63

Download references

Acknowledgements

This work was supported by Grants from the National Key Technologies R&D Program (no. 2015BAI13B09), National Science and Technology Major Project (no. 2013ZX10002004) and Key Project from Beijing Municipal Science and Technology Commission (no. D121100003912003).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jidong Jia.

Ethics declarations

Ethical requirements

This article does not contain any studies with human participants or animals performed by either of the authors.

Conflict of interest

Qiuju Tian and Jidong Jia declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tian, Q., Jia, J. Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia. Hepatol Int 10, 854–860 (2016). https://doi.org/10.1007/s12072-016-9745-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-016-9745-2

Keywords

Navigation